Physiopathology and treatment of viral hepatitis (VHEP)
Department Hepato-Gastroenterology Department
The Team Project
Hepatitis B virus (HBV) infection remains a major global health concern as over 257 million individuals are estimated to be carriers of hepatitis B ‘surface’ antigen (HBsAg), the hallmark of chronic HBV infection (CHB). CHB has potential adverse outcomes, including cirrhosis, hepatic decompensation, and hepatocellular carcinoma.
The Hepatology team from Hospital Beaujon is a worldwide leader in clinical trials and has been successful in drug development for chronic hepatitis C, for which the team has been involved as a coordinator/principal investigator in several clinical trials. In particular the team coordinated major international clinical trials on HCV Genotype 4 infection.
The team project is currently working on HBV physiopathology and for strategies to achieve HBV cure. The team is involved as a coordinator/principal investigator in several clinical trials on drugs in development to fight against HBV infection. The team fields of research include also chronic liver diseases, translational medicine and treatment of HBV and HCV infections with new direct-acting antivirals.
The development of antibodies against HBsAg is a hallmark of the resolution of acute infection and is a therapeutic goal for the functional recovery of CHB. CHB causes exhaustion of virus-specific T cells, but its impact on humoral immunity has been poorly studied. The identification of T and B cell response mechanisms will provide a better understanding of their role in seroconversion of HBsAg.
Thanks to the expertise of Dr Abdellah Mansouri, the team has also a project on mitochondrial involvement in the pathophysiology of viral hepatitis. Mitochondria play important role in cellular antiviral defense because they serve as the platform for innate immune signaling and for inflammasome formation. The mitochondrial unfolded protein response (UPRmt, a recently discovered protein quality control pathway that resolves the mitochondrial stress by retrograde signaling to the nucleus) is characterized by transcriptional activation of innate immune and proinflammatory genes. Mitophagy and UPRmt may thus act as a negative modulator of mitochondrial antiviral protein (MAVS)-mediated innate immune signaling and may unravel how HBV or HCV usurp mitochondrial dysfunction to cripple the interferon synthesis, interferon responsive genes expression and cellular antiviral response. One of the objectives of the Team is thus to demonstrate viral involvement in mitochondrial dynamics (biogenesis, fission, fusion, mitophagy), function/dysfunction, oxidative stress and UPRmt. These studies may highlight the novel role of mitochondrial stresses in antiviral signaling and in the responses to the treatments.
Publication date : 07 October 2020 More
COVID-19: discovery, diagnostics and drug development Journal of Hepatology
Autors : Asselah Tarik David Durantel Eric Pasmant George Lau Raymond F. Schinazi
Publication date : 01 August 2020 More
Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development J Hepatol .
Autors : Tout Issam Alex Loureiro Dimitri Mansouri Abdellah Vassili Soumelis Boyer Nathalie Asselah Tarik
Publication date : 01 November 2019 More
Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure Lancet Gastroenterol Hepatol
Autors : Asselah Tarik Loureiro Dimitri Boyer Nathalie Mansouri Abdellah
Publication date : 01 January 2019 More
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial Lancet Gastroenterol Hepatol
Autors : Asselah Tarik Samuel S Lee Betty B Yao Tuan Nguyen Florence Wong Adam Mahomed Seng Gee Lim Armand Abergel Joe Sasadeusz Edward Gane Neddie Zadeikis Gretja Schnell Zhenzhen Zhang Ariel Porcalla Federico J Mensa Kinh Nguyen
Publication date : 01 September 2018 More
Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases Gastroenterology .
Autors : Mansouri Abdellah Charles-Henry Gattolliat Asselah Tarik
Publication date : 01 April 2018 More
Eliminating hepatitis C within low-income countries – The need to cure genotypes 4, 5, 6 J Hepatol
Autors : Asselah Tarik Tarek Hassanein Imam Waked Mansouri Abdellah Geoffrey Dusheiko Edward Gane
Publication date : 01 March 2018 More
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Clin Gastroenterol Hepatol
Autors : Asselah Tarik Kris V Kowdley Neddie Zadeikis Stanley Wang Tarek Hassanein Yves Horsmans Massimo Colombo Filipe Calinas Humberto Aguilar Victor de Ledinghen Parvez S Mantry Christophe Hezode Rui Tato Marinho Kosh Agarwal Frederik Nevens Magdy Elkhashab Jens Kort Ran Liu Teresa I Ng Preethi Krishnan Chih-Wei Lin Federico J Mensa
Publication date : 01 February 2018 More
Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int .
Autors : Asselah Tarik Marcellin Patrick Raymond F Schinazi
Publication date : 01 February 2018 More
Towards HBV curative therapies Liver Int.
Autors : Raymond F. Schinazi Maryam Ehteshami Leda Bassit Asselah Tarik
Publication date : 12 October 2016 More
MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C Scientific Reports
Autors : Kevin Appourchaux Dokmak Safi Matthieu Resche-Rigon Treton Xavier Martine Lapalus Charles-Henry Gattolliat Emmanuelle Porchet Michelle Martinot-Peignoux Boyer Nathalie Michel Vidaud Bedossa Pierre Marcellin Patrick Ivan Bièche Emilie Estrabaud Asselah Tarik
Publication date : 26 March 2014 More
Reduction of MicroRNA 122 Expression in IFNL3 CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C J Virol, 2014 Jun;88(11):6394-402. doi: 10.1128/JVI.00016-14
Autors : Estrabaud E Lapalus M Broët P Appourchaux K Muynck SD Lada O Martinot-Peignoux M Bièche I Valla Dominique Bedossa Pierre Marcellin Patrick Vidaud M Asselah Tarik